ORX-750

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024. “Centessa is proud to be at the forefront of developing OX2R agonists, a groundbreaking new drug class with the potential to transform the standard of care for patients across multiple therapeutic areas,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “Our team’s drug optimization techniques have enabled a growing pipeline of novel, potential best-in-class OX2R agonists aimed at restoring normative wakefulness for individuals living with excessive daytime sleepiness (EDS) in neurological, neurodegenerative and neuropsychiatric disorders, and potentially addressing other key symptoms such as impaired attention, cognitive deficits and fatigue.” Dr. Saha continued, “Our most advanced OX2R agonist, ORX750, is progressing in the Phase 2a CRYSTAL-1 study for the treatment of NT1, NT2 and IH, and is on track with data expected across all three indications this year. Data from the Phase 1 study of ORX750 showed compelling activity in acutely sleep-deprived healthy volunteers at low doses with a favorable initial safety and tolerability profile. Based on the strength of these data, we believe ORX750 has the potential to be best-in-class and to enable the full range of doses required to meet the needs of patients living with NT1, NT2 and IH. We look forward to sharing data this year and expect the Phase 2a study to enable dose selection for future registrational studies of ORX750.” Dr. Saha concluded, “In addition to the transformational potential of ORX750 for individuals living with sleep-wake disorders, we see tremendous opportunity with our follow-up OX2R agonists that are being advanced for the treatment of EDS, impaired attention, cognitive deficits and fatigue in neurological, neurodegenerative and neuropsychiatric disorders. ORX142 is progressing in IND-enabling studies, and subject to IND clearance, we expect to initiate clinical development and share clinical data in acutely sleep-deprived healthy volunteers this year. We are also pleased to have ORX489, our most potent OX2R agonist to date based on preclinical data, advancing in IND-enabling studies. With this ongoing momentum across our pipeline, we expect 2025 to be an exciting, data-rich year for Centessa.” Recent Highlights In January 2025, the Company shared positive data from the Phase 1 clinical study of ORX750, a highly potent and selective OX2R agonist, in healthy volunteers as of December 5, 2024, the most recent data cutoff date. These data showed ORX750 significantly increased wakefulness in acutely sleep-deprived healthy volunteers compared to placebo at all doses tested, with a clear dose response. More specifically, in the 2.5 mg (n=8), 3.5 mg (n=10) and 5.0 mg (n=8) dose cohorts, ORX750 was shown to restore normative wakefulness with mean sleep latencies (MSL) >30 minutes (out of a score of 40 minutes) as measured by the Maintenance of Wakefulness Test (MWT); the 5.0 mg dose cohort achieved an MSL of 38 minutes, compared to 15 minutes for placebo. A favorable safety and tolerability profile was observed with all treatment-emergent adverse events (AEs) being transient with none leading to treatment discontinuation. There were no cases of hepatotoxicity or visual disturbances observed. Additionally, there were no clinically significant treatment-emergent changes in hepatic and renal parameters, vital signs or ECG parameters. These data also showed linear pharmacokinetics (PK) with a profile that supports the use of ORX750 as a once-daily oral dosing regimen with rapid absorption. The Company believes these data continue to support ORX750’s profile as a potential best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, with first-in-class potential in NT2 and IH. Data from the Phase 1 study of ORX750 will be presented in a poster session at the American Academy of Neurology (AAN) Annual Meeting on April 5, 2025.In November 2024, the Company announced the initiation of the Phase 2a CRYSTAL-1 study of ORX750 in participants with NT1, NT2 and IH. Pipeline and Anticipated Upcoming Milestones ORX750: Phase 2a CRYSTAL-1 study ongoing in participants with NT1, NT2 and IH. The Company expects to share Phase 2a data across all three indications in 2025. In addition, data from the Phase 1 study will be presented in a poster session at the AAN Annual Meeting on April 5, 2025.ORX142: Advancing through IND-enabling studies. The Company is focused on obtaining IND clearance and initiating clinical development with the goal of sharing clinical data in acutely sleep-deprived healthy volunteers in 2025.ORX489: Advancing in IND-enabling studies. Fourth Quarter and Full-Year 2024 Financial Results Cash, Cash Equivalents and Short-term Investments: Cash, cash equivalents and short-term investments totaled $482.2 million as of December 31, 2024. The Company expects its cash, cash equivalents and short-term investments as of December 31, 2024 will fund operations into mid-2027.Research & Development (R&D) Expenses: R&D expenses were $60.9 million for the fourth quarter ended December 31, 2024, compared to $29.7 million for the fourth quarter ended December 31, 2023, and $150.2 million for the full-year 2024 compared to $124.4 million for the full-year 2023. R&D expenses for the quarter and full-year 2024 included a one-time charge of $31.5 million related to the discontinuation of the global clinical development program for SerpinPC that was being progressed for the treatment of hemophilia B.General & Administrative Expenses: General and administrative expenses were $13.7 million for the fourth quarter ended December 31, 2024, compared to $12.3 million the fourth quarter ended December 31, 2023, and $50.8 million for the full-year 2024 compared to $53.7 million for the full-year 2023.Net Loss Attributable to Ordinary Shareholders (Net loss): Net loss was $111.3 million for the fourth quarter ended December 31, 2024, compared to $36.8 million for the fourth quarter ended December 31, 2023, and $235.8 million for the full-year 2024 compared to $151.1 million for the full-year 2023. Net loss for the quarter and full-year 2024 reflects non-recurring items including a $34.1 million loss on debt extinguishment and a charge of $31.5 million related to the discontinuation of the global clinical development program for SerpinPC which was included in R&D expenses. In addition, net loss for full-year 2023 included a non-recurring non-cash tax benefit of $24.2 million. About the Phase 2a CRYSTAL-1 Clinical Study of ORX750The Phase 2a CRYSTAL-1 study is a randomized, double-blind, placebo-controlled, cross-over basket study to evaluate the safety, tolerability, and PK of ORX750 in participants with NT1, NT2 and IH. There are separate cohorts for each indication. Initial dosing is 1.0 mg for NT1 and 2.0 mg for NT2 and IH with sequential dose escalation/de-escalation between cohorts. Each dosing cohort consists of a 6-week treatment duration with crossover study design. During the 6 weeks of treatment, each participant will be randomized to one of two blinded treatment sequences and receive a total of 4 weeks of treatment with ORX750 and 2 weeks of treatment with placebo. Efficacy assessments will evaluate the effect of ORX750 on excessive daytime sleepiness (using the MWT and Epworth Sleepiness Scale (ESS)), cataplexy (NT1 only) and overall symptom improvement (measured by Narcolepsy Severity Scale (NSS) and Idiopathic Hypersomnia Severity Scale (IHSS)). Other exploratory assessments include measures of sleep, cognition, attention, memory and general health. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. We also have an early-stage immuno-oncology program focused on our novel LockBody® technology platform. For more information, visit www.centessa.com, which does not form part of this release. Forward Looking Statements This press release contains forward-looking statements. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” “aim,” “seek,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company’s ability to discover and develop transformational medicines for patients; its expectations for executing on the Company's pipeline; its expectations on its anticipated cash runway; the timing of commencement of new studies or clinical trials or clinical and preclinical data related to ORX750, ORX142, ORX489 and other OX2R agonist molecules, and the LockBody technology platform; its ability to identify, screen, recruit and maintain a sufficient number of or any subjects in its existing and anticipated studies or clinical trials of ORX750, ORX142, ORX489 and other OX2R agonist molecules, and any LockBody candidates; its expectations on executing its research and clinical development plans and the timing thereof; its expectations as to the potential results and impact of each of its clinical programs and trials; the Company’s ability to differentiate ORX750, ORX142, ORX489 and other OX2R agonist molecules, any LockBody candidates from other treatment options; the development, design and therapeutic potential of ORX750, ORX142, ORX489 and other OX2R agonist molecules, and the LockBody technology platform; the anticipated net savings associated with the discontinuation of the SerpinPC program; and regulatory matters, including the timing and likelihood of success of obtaining regulatory clearance, obtaining authorizations to initiate or continue clinical trials. Any forward-looking statements in this press release are based on our current expectations, estimates, assumptions and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to identify, screen and recruit a sufficient number of or any subjects in our existing and anticipated new studies or clinical trials of ORX750, ORX142, ORX489 or within anticipated timelines; our expectations relating to the clinical trials of ORX750, including the predicted timing of enrollment, the predicted efficacious doses of ORX750 and our ability to successfully conduct our clinical development of ORX750, our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing product candidates and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oxford Finance, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; our operating costs and use of cash, including cash runway, cost of development activities and conducting clinical trials, future expenditures risks; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the historical results of preclinical studies or clinical studies will not be predictive of future results in ongoing or future studies; economic risks to the United States and United Kingdom banking systems; and geo-political risks such as the Russia-Ukraine war or the Middle East conflicts. These and other risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission (SEC). We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law. Contact:Kristen K. Sheppard, Esq.SVP of Investor Relationsinvestors@centessa.com Centessa Pharmaceuticals plcConsolidated Statements of Operations and Comprehensive Loss(unaudited)(amounts in thousands except share and per share data) Quarter EndedDecember 31, 2024 Quarter EndedDecember 31, 2023 Year EndedDecember 31, 2024 Year EndedDecember 31, 2023License and other revenue $— $6,853 $— $6,853 Operating expenses: Research and development 60,874 29,716 150,244 124,405 General and administrative 13,706 12,315 50,811 53,731 Loss from operations (74,580) (35,178) (201,055) (171,283)Interest income 4,845 2,933 14,016 10,476 Interest expense (2,479) (2,570) (10,090) (9,906)Loss on extinguishment of debt (34,097) — (34,097) — Other non-operating expenses, net (3,968) (878) (1,687) (5,428)Loss before income taxes (110,279) (35,693) (232,913) (176,141)Income tax expense (benefit) 1,050 1,144 2,844 (25,056)Net loss (111,329) (36,837) (235,757) (151,085) Other comprehensive income: Foreign currency translation adjustment 1,721 459 1,223 1,700 Unrealized gain on available for sale securities, net of tax 397 255 1,497 1,290 Other comprehensive income 2,118 714 2,720 2,990 Total comprehensive loss $(109,211) $(36,123) $(233,037) $(148,095) Net loss per ordinary share - basic and diluted $(0.84) $(0.38) $(2.06) $(1.57)Weighted average ordinary shares outstanding - basic and diluted 132,050,271 97,923,585 114,473,449 96,177,578 Centessa Pharmaceuticals plcCondensed Consolidated Balance Sheets(unaudited)(amounts in thousands) December 31, 2024 December 31, 2023Total assets: Cash and cash equivalents$383,221 $128,030Short-term investments 98,956 128,519Other assets 94,621 103,697Total assets$576,798 $360,246 Total liabilities Other liabilities$66,313 $48,302Long term debt 108,940 75,700Total liabilities 175,253 124,002 Total shareholders’ equity 401,545 236,244Total liabilities and shareholders' equity$576,798 $360,246

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2024. The full report can be viewed here. Chris Cargill, President & CEO of Nxera, commented: “2024 was a transformational year for Nxera during which we made excellent progress under our new company name and brand towards becoming a leading technology driven biopharmaceutical company bringing new medicines to patients in Japan and globally. “We made fantastic commercial progress, with two products – PIVLAZ™ and QUVIVIQ™ (partnered with Shionogi) – recently launched in Japan driving top line revenue growth. We plan to make these products available to patients in South Korea shortly, in addition to other key APAC markets (ex-China). “Furthermore, and importantly, we saw significant advances across our partnered pipeline in 2024, with multiple programs moving towards late-stage clinical development and generating approximately US$90 million in upfront and milestone payments. These programs address some of the fastest growing therapeutic areas of unmet need, including neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. The progress made by partner Neurocrine to advance its muscarinic agonist portfolio during the year has been particularly exciting and will lead to the first Nxera-designed molecule entering Phase 3 trials in 2025. “Our three wholly owned programs are also advancing as planned in early clinical development, with several important milestones expected over the next 12-18 months. Further, the continued investment in our NxWave™ platform, alongside our collaborations with cutting-edge technology companies, is generating exciting new discovery opportunities within the GPCR target universe, and potentially beyond to other important transmembrane target classes, such as ion channels or transporters. In addition, it allows us to explore new modalities against GPCR targets of interest, such as peptides and antibodies, broadening our capabilities and opportunities even more. “Going into 2025, Nxera is well capitalized and very well positioned – with multiple clinical data readouts and other potential catalysts expected during the year – to build on the tremendous work done by our exceptional and dedicated team, as we continue our mission to bring innovative therapies to patients in Japan and around the world.” Operational Highlights for Q4 2024 Significant growth in PIVLAZ® (clazosentan sodium) 150mg sales in Japan during first full year of Nxera ownership Rapidly becoming standard of care in Japan with neurosurgeons for prevention of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage (aSAH)Market share increased from 57% in 2023 to 69% in 2024Q4 2024 net sales of JPY 4,282 million, FY 2024 net sales of JPY 12,651 million (US$83.5 million, representing 14% growth vs FY 2023) QUVIVIQ™ (daridorexant) 25 and 50 mg launched in Japan for the treatment of adult patients with insomnia Insomnia affects about 20% of Japanese adults and is recognized as an important national issue impacting both physical and mental health.QUVIVIQ™ is a novel dual orexin receptor agonist that was successfully developed through a Phase 3 trial by Nxera Pharma Japan (“NPJ,” a wholly owned subsidiary of Nxera Pharma).QUVIVIQ™ was launched in December 2024 under a commercial partnership agreement signed in October 2024 with Shionogi, which is solely responsible for distribution and sales of QUVIVIQ™ in Japan. NPJ is responsible in part for provision of drug product. Strategy to expand market for daridorexant underway with start of Phase 3 trial in South Korea Insomnia affects an estimated 15-25% of the adult population in South Korea, or 6.5-11 million people. The randomized, double-blind, placebo-controlled Phase 3 study in adult and elderly subjects with insomnia is expected to run for 12 months with results expected during 1H 2026. Further progress in sleep/wake disorders made by partner Centessa, which initiated a Phase 2 trial of ORX750 ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 agonist, designed using Nxera technology to target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and other sleep-wake disorders. New multi-target partnership and licensing agreement with UK techbio company Antiverse to design antibodies for validated but challenging GPCR targets The collaboration combines Antiverse’s generative AI antibody design expertise with Nxera’s NxWave™ platform, with Nxera retaining exclusive rights to develop and commercialize any resulting candidates. Experienced Pharma Executive Makoto Sugita, M.D., Ph.D., MBA, Appointed as Chief Medical Officer and President of NPJ Dr. Sugita was formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – he brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies. Nxera Pharma won Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 Awards recognize outstanding advancements and innovations in the Japanese pharma and biotech sector. Post-period Events Clinical development progress with partnered muscarinic agonist portfolio noted by Neurocrine at 43rd Annual J.P. Morgan Healthcare Conference NBI-1117568 (an oral, muscarinic M4-selective agonist) End of Phase 2 meeting with the US Food & Drug Administration completed and reiteration of plans to begin Phase 3 studies in schizophrenia in 1H 2025.Initiate Phase 2 study in bipolar mania in 2H 2025. NBI-1117570 (a dual M1 / M4 agonist) Initiate Phase 2 study in schizophrenia in 2H 2025. NBI-1117567 (an M1-preferring agonist) and NBI-1117569 (an M4-preferring agonist) Phase 1 trials underway targeting neurological and neuropsychiatric conditions with data readouts anticipated during 2025. Operational Highlights for Full Year 2024 Corporate highlights Nxera Pharma, the new name for Sosei Heptares, came into effect on 1 April 2024 along with the launch of a new corporate brand and identity designed to capture the Group’s ambition to be at the forefront of the next era of biopharmaceuticals and medicineSenior team strengthened with appointments of experienced biopharma executives Toshihiro Maeda as Chief Operating Officer and senior strategy consultant Patrick Branch as Head of Business Development for Japan and APAC Progress with in-house programs Approval of QUVIVIQ™ (daridorexant) 25 and 50 mg by the Ministry of Health, Labour and Welfare of Japan for the treatment of adult patients with insomnia received in September 2024First subject dosed in a Phase 1 trial with NXE0033744, a novel, potent, selective and gut-restricted EP4 receptor agonist in development for the treatment of Inflammatory Bowel Disease (IBD) Full ownership of NXE0027477 regained from GSK – NXE-477 is a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for IBD. Nxera and PrecisionLife expanded their 2022 strategic R&D partnership into autoimmune disorders with the aim of identifying new drug targets and subsequently potential precision targeted therapies for complex, chronic conditions. Progress with partnered programs Approximately US$70 million in milestone payments received by Nxera based on progress made across multiple partnered programs Neurocrine presented positive Phase 2 data for schizophrenia candidate NBI-‘568 and announced its intention to advance it into Phase 3 trials in 2025, triggering a US$35 million payment to Nxera.Successful completion of long-term preclinical toxicity program with NBI-‘568, supporting its chronic dosing in future clinical trials, triggered a US$15 million payment from Neurocrine First R&D milestone reached under a multi-target discovery collaboration with AbbVie in neurological diseases resulted in a payment of US$10 million to NxeraProgress made by Centessa advancing ORX750 into and through Phase 1 development resulted in a milestone payment to Nxera of US$4.6 million US$2.5 million milestone payment received from Formosa Pharmaceuticals for US approval of APP13007 for the treatment of post-operative inflammation and pain following ocular surgery New global collaboration and exclusive option-to-license agreement signed with Boehringer Ingelheim to develop first-in-class treatments targeting all symptoms of schizophrenia Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Nxera with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaNxera received EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totalling up to EUR 670 million plus tiered royalties Financial Highlights for the 12-month Period ended 31 December 2024 Revenue totalled JPY 28,835 million (US$190.4 million*), an increase of JPY 16,069 million (US$99.6 million) vs. the prior year. This increase was primarily due to the inclusion of NPJ in the scope of consolidation from July 2023 resulting in twelve months of PIVLAZ® sales being included in 2024 compared to circa five months in 2023, as well as signing one new R&D partnership agreement and the occurrence of five R&D milestone events in the current year vs. no upfront fees and the occurrence of three R&D milestone events in the prior year. R&D expenses totalled JPY 11,816 million (US$78.0 million), an increase of JPY 1,741 million (US$6.3 million) vs. the prior year. This increase primarily reflects an increased investment in R&D plus the impact of the weaker Yen. JPY 1,483 million (US$9.8 million) has been included for R&D expenses relating to NPJ/NPK.SG&A expenses totalled JPY 16,015 million (US$105.8 million), an increase of JPY 6,050 million (US$34.8 million) vs. the prior corresponding period. This increase was primarily due to an increase in SG&A expenses relating to the NPJ/NPK businesses, including an amortization charge on Idorsia related intangible assets. JPY 8,972 million (US$59.3 million) has been included for SG&A expenses relating to NPJ/NPK.Operating loss totalled JPY 5,423 million (US$35.8 million) vs. an operating loss of JPY 9,526 million (US$67.8 million) in the prior year. This improvement in profitability reflects the combined effect of all movements explained above.Loss before income tax totalled JPY 4,662 million (US$30.8 million) vs. a loss before income tax of JPY 10,680 million (US$76.0 million) in the prior year. This improvement in profitability reflects the combined effect of all movements explained above.Net loss for the year ended 31 December 2024 totalled JPY 4,838 million (US$31.9 million) vs. a net loss of JPY 7,193 million (US$51.2 million) in the prior year. This improvement in profitability reflects the combined effect of all movements explained above.Core operating profit** totalled JPY 3,606 million (US$23.8 million) vs. a core operating loss of JPY 3,076 million (US$21.9 million) in the prior corresponding period. Cash and cash equivalents as at 31 December 2024 amounted to JPY 32,268 million (US$205.8 million) having decreased by JPY 16,797 million (decreased by US$142.1 million) from the beginning of the year. *Convenience conversion to US$ at the following rates: FY 2024: 1US$ =151.43 JPY; FY 2023: 1US$ =140.53 JPY; 31 Dec 2024: 1US$ = 156.83 JPY; 31 Dec 2023: 1US$ = 141.03 JPY ** Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWaveTM platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment FY24YE Tanshin_NxeraPharma